CVT-301 for the treatment of Parkinson’s disease

References

• Thenganatt M, Jankovic J. The relationship between essential tremor and Parkinson’s disease. Parkinsonism Related Disord. 2015;22:S162–5.
   PubMed Web of Science ®Google Scholar
• Lang AE, Kalia LV. Parkinson’s disease. Lancet. 2015;386:896–912.
   PubMed Web of Science ®Google Scholar
• Parkinson J. An essay on the shaking palsy. London: sherwood, Neely and Jones; 1817. Reprinted in: neuropsychiatric classics. J Neuropsychiatry Clin Neurosci. 2002;14:223–236.
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. A brief history of LD. J Neurol. 2010;257:249–252.
   PubMed Web of Science ®Google Scholar
• Fahn S. The history of dopamine and LD in the treatment of Parkinson’s disease. Mov Disord. 2008;23:S497–508.
   PubMed Web of Science ®Google Scholar
• Aquino CC, Fox SH. Clinical spectrum of LD-induced complications. Mov Disord. 2015;30:80–90.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Hauser RA, Grosset DG, et al. A randomized trial of inhaled LD (CVT-301) for motor fluctuations in Parkinson’s Disease. Mov Disord. 2016;31:1356–1365.
   PubMed Web of Science ®Google Scholar
• Fahn S, Jankovic J, Hallet M. Principles and practice of movement disorders. 2nd ed. Philadelphia: Elsevier Saunders; 2011.
   Google Scholar
• Accorda Therapeutics. News release. Acorda Therapeutics Announces FDA Approval of INBRIJA™ (LD inhalation powder). [cited 2019 Feb 10]. http://s1.q4cdn.com/271808180/files/doc_news/Acorda-Therapeutics-Announces-FDA-Approval-of-INBRIJA-LD-inhalation-powder.pdf
   Google Scholar
• Stacy M, Silver D. Apomorphine for the acute treatment of “off” episodes in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14:85–92.
   PubMed Web of Science ®Google Scholar
• Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord. 2005;20:224–230.
   PubMed Web of Science ®Google Scholar
• Freitas ME, Ruiz-Lopez M, Fox SH. Novel LD formulations for Parkinson’s disease. CNS Drugs. 2016;30:1079–1095.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord. 2016;31:1366–1372.
   PubMed Web of Science ®Google Scholar
• Jankovic J. LD strengths and weaknesses. Neurology. 2002;58:S19–32.
   PubMed Web of Science ®Google Scholar
• Margolesky J, Singer C. Extended-release oral capsule of CD-LD in Parkinson disease. Ther Adv Neurol Disord. 2017;11:1756285617737728. Published 2017 Oct 30. .
   Web of Science ®Google Scholar
• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311:1670–1683.
   Google Scholar
• Bette S, Shpiner DS, Singer C, et al. Safinamide in the management of patients with Parkinson’s disease not stabilized on LD: a review of the current clinical evidence. Ther Clin Risk Manag. 2018;14:1737–1745.
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim S-Y, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011;26:S2–41.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Ferreira JJ, Lees A, et al. Opicapone for the treatment of Parkinson’s disease: a review of a new licensed medicine. Mov Disord. 2018;33:1528–1539.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Rizos A, Sethi K. Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery? J Neural Transm. 2013;120:1305–1320.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Chaudhuri KR, LeWitt P, et al. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses. Clin Neuropharmacol. 2015;38:89–103.
   PubMed Web of Science ®Google Scholar
• Grosset KA, Malek N, Morgan F, et al. Inhaled apomorphine in patients with “on-off” fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study. J Parkinsons Dis. 2013;3:31–37.
   PubMedGoogle Scholar
• Koller W, Stacy M. Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology. 2004;62:S22–6.
   PubMed Web of Science ®Google Scholar
• Esteban Munoz J, Marti MJ, Marin C, et al. Long-term treatment with intermittent intranasal or subcutaneous apomorphine in patients with levodopa-related motor fluctuations. Clin Neuropharmacol. 1997;20:245–252.
   PubMed Web of Science ®Google Scholar
• Auffret M, Le Jeune F, Maurus A, et al. Apomorphine pump in advanced Parkinson’s disease: effects on motor and nonmotor symptoms with brain metabolism correlations. J Neurol Sci. 2017;372:279–287.
   PubMed Web of Science ®Google Scholar
• Acorda Therapeutics Inc. ARCUS Technology. n.d. 2019 Jan 20 Available from: http://www.acorda.com/products/arcus-technology
   Google Scholar
• Freed MI, Batycky R, Merica E. Safety, tolerability and LD pharmacokinetics following inhaled administration of CVT-301, a LD dry powder aerosol, in healthy, adult subjects. Mov Disord. 2013;28(Suppl1):430.
   Google Scholar
• Bartus RT, Emerich D, Snodgrass-Belt P, et al. A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson’s disease. J Pharmacol Exp Ther. 2004;310:828–835.
   PubMed Web of Science ®Google Scholar
• Lipp MM, Batycky R, Moore J, et al. Preclinical and clinical assessment of inhaled LD for OFF episodes in Parkinson’s disease. Sci Transl Med. 2016;8:360ra136.
   PubMed Web of Science ®Google Scholar
• DeLong M, Wright J, Dawson M, et al. Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates. J Aerosol Med. 2005;18:452–459.
   PubMedGoogle Scholar
• Dunbar C, Scheuch G, Sommerer K, et al. In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int J Pharm. 2002;245:179–189.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18–31.
   PubMed Web of Science ®Google Scholar
• Healy AM, Amaro MI, Paluch KJ, et al. Dry powders for oral inhalation free of lactose carrier particles. Adv Drug Deliv Rev. 2014;8:32–35.
   Web of Science ®Google Scholar
• Stocchi F, Vacca L, Stirpe P, et al. Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2018;14:1189–1195.
   PubMed Web of Science ®Google Scholar
• Khor S, Hsu A. The pharmacokinetics and pharmacodynamics of LD in the treatment of Parkinson’s Disease. Curr Clin Pharmacol. 2007;2:234–243.
   PubMedGoogle Scholar
• InbrijaTM (LD inhalation powder) [package insert]. [cited 2019 Feb 10]. https://www.inbrija-hcp.com/
   Google Scholar
• Ellenbogen A, Hauser RA, Isaacson SH. Inhaled LD administered with oral CD/LD for early morning OFF symptoms in patients with Parkinson’s Disease: safety assessment. Neurology. 2018;90:S26.005.
   Web of Science ®Google Scholar
• Whitfield AC, Moore BT, Daniels RN. Classics in chemical neuroscience: LD. ACS Chem Neurosci. 2014;5:1192–1197.
   PubMed Web of Science ®Google Scholar
• Freed MI, Moore JA, Batycky R, et al. Pharmacokinetics (PK) following inhaled LD delivery with CVT-301: rapid augmentation of systemic LD (LD) levels and improvement in motor function in PD patients with motor fluctuations. Mov Disord. 2014;29:S1:647.
   Google Scholar
• LeWitt PA, Hauser RH, Grosset DG, et al. A Randomized Trial of Inhaled LD (CVT-301) for motor fluctuations in Parkinson’s Disease. Mov Disord. 2016;31:1356.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy if CVT-301 (LD inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18:145–154.
   PubMed Web of Science ®Google Scholar
• Grosset D, Dhall R, Gurevich T. Long-term efficacy of inhaled LD in Parkinson’s Disease subjects with motor fluctuations: a phase 3 open-label randomized study. Neurology. 2018;90:S26.008.
   Web of Science ®Google Scholar
• Grosset D, Dhall R, Gurevich T. Long-term pulmonary safety of inhaled LD in Parkinson’s Disease subjects with motor fluctuations: a phase 3 open-label randomized study. Neurology. 2018;90(15 Suppl):S26.006.
   Google Scholar
• Isaacson SH, Ellenbogen A, Hauser RA. Inhaled LD administered with oral CD/LD for early morning OFF symptoms in patients with Parkinson’s Disease: exploratory efficacy analysis. Neurology. 2018;90:S26.004.
   Google Scholar
• Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology. 2004;62:S12–17.
   PubMed Web of Science ®Google Scholar
• Torsney KM, Forsyth D. Respiratory dysfunction in Parkinson’s disease. J R Coll Physicians Edinb. 2017;47:35–39.
   PubMed Web of Science ®Google Scholar
• Hampson NB, Kieburtz KD, LeWitt PA, et al. Prospective evaluation of pulmonary function in Parkinson’s disease patient with motor fluctuations. Int J Neurosci. 2017;127:276–284.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Poewe W, Brooks D. Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features. Mov Disord. 2018;33:909–918.
   PubMed Web of Science ®Google Scholar
• Muller T, Muhlack S. Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson’s disease patients. J Neural Transm (Vienna). 2014;121:643–648.
   PubMed Web of Science ®Google Scholar
• Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized delayed-start trial of levodopa in Parkinson’s disease. N Engl J Med. 2019;380:315–324.
   PubMed Web of Science ®Google Scholar
• Hauser R, Isaacson S, Espay A, et al. Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase [abstract]. Mov Disord. 2017;32:S2.
   PubMed Web of Science ®Google Scholar